Paper36264792
Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators.
Fiedorczuk K and 1 other. Science, 2022. Cited by 152 papers, by iCite.
Cite this record
ConductScience Library. Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators. Papers, record 36264792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36264792
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cystic Fibrosis Transmembrane Conductance Regulator | Major topic |
| Phenylalanine | Major topic |
| Sequence Deletion | Major topic |
| Cystic Fibrosis | Major topic |
| Cryoelectron Microscopy | |
| Humans | |
| Protein Conformation | |
| Drug Synergism | |
| Aminophenols | |
| Drug Combinations | |
| Indoles | |
| Pyrazoles | |
| Pyridines | |
| Quinolines | |
| Benzodioxoles | |
| Quinolones |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Howard Hughes Medical Institute | United States | PubMed |
Source PubMed
References71
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15729345 | CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. | Nature | 2005 | https://conductscience.org/library/papers/15729345 | PubMed |
| 2 | 15264254 | UCSF Chimera--a visualization system for exploratory research and analysis. | J Comput Chem | 2004 | https://conductscience.org/library/papers/15264254 | PubMed |
| 3 | 22138491 | CFTR: folding, misfolding and correcting the ΔF508 conformational defect. | Trends Mol Med | 2012 | https://conductscience.org/library/papers/22138491 | PubMed |
| 4 | 16339147 | Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis. | J Biol Chem | 2006 | https://conductscience.org/library/papers/16339147 | PubMed |
| 5 | 20667826 | The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20667826 | PubMed |
| 6 | 23104983 | Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. | FASEB J | 2013 | https://conductscience.org/library/papers/23104983 | PubMed |
| 7 | 34995514 | Mechanism of CFTR correction by type I folding correctors. | Cell | 2022 | https://conductscience.org/library/papers/34995514 | PubMed |
| 8 | 33775603 | Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. | J Cyst Fibros | 2021 | https://conductscience.org/library/papers/33775603 | PubMed |
| 9 | 23666117 | Mechanism-based corrector combination restores ΔF508-CFTR folding and function. | Nat Chem Biol | 2013 | https://conductscience.org/library/papers/23666117 | PubMed |
| 10 | 28340353 | Molecular Structure of the Human CFTR Ion Channel. | Cell | 2017 | https://conductscience.org/library/papers/28340353 | PubMed |
| 11 | 11600681 | A cluster of negative charges at the amino terminal tail of CFTR regulates ATP-dependent channel gating. | J Physiol | 2001 | https://conductscience.org/library/papers/11600681 | PubMed |
| 12 | 2475911 | Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. | Science | 1989 | https://conductscience.org/library/papers/2475911 | PubMed |
| 13 | 28735752 | Conformational Changes of CFTR upon Phosphorylation and ATP Binding. | Cell | 2017 | https://conductscience.org/library/papers/28735752 | PubMed |
| 14 | 30334692 | VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30334692 | PubMed |
| 15 | 1718606 | Nucleoside triphosphates are required to open the CFTR chloride channel. | Cell | 1991 | https://conductscience.org/library/papers/1718606 | PubMed |
| 16 | 20590134 | The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface. | Biochemistry | 2010 | https://conductscience.org/library/papers/20590134 | PubMed |
| 17 | 33303536 | Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. | Eur Respir J | 2021 | https://conductscience.org/library/papers/33303536 | PubMed |
| 18 | 15528182 | Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15528182 | PubMed |
| 19 | 9920908 | Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal. | J Biol Chem | 1999 | https://conductscience.org/library/papers/9920908 | PubMed |
| 20 | 27469176 | Background and Epidemiology. | Pediatr Clin North Am | 2016 | https://conductscience.org/library/papers/27469176 | PubMed |
Cited by107
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 152 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42707060 | Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis. | iScience | 2026 | https://conductscience.org/library/papers/42707060 | PubMed |
| 42675037 | Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42675037 | PubMed |
| 42654157 | Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42654157 | PubMed |
| 42601390 | Triple potentiator combinations increase the functional correction of several CFTR gating mutants. | NPJ Drug Discov | 2026 | https://conductscience.org/library/papers/42601390 | PubMed |
| 42589573 | Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589573 | PubMed |
| 42582698 | Unique fluoroalkyl substituents: is there life after CF3? | Chem Sci | 2026 | https://conductscience.org/library/papers/42582698 | PubMed |
| 42488778 | Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases. | Isr J Chem | 2024 | https://conductscience.org/library/papers/42488778 | PubMed |
| 42403151 | Regulation of CFTR stability at the plasma membrane-Mechanisms and therapeutic opportunities in cystic fibrosis. | FEBS Lett | 2026 | https://conductscience.org/library/papers/42403151 | PubMed |
| 42282787 | Profiling the CFTR Variant Selectivity and Off-Target Interactions of VX-121. | bioRxiv | 2026 | https://conductscience.org/library/papers/42282787 | PubMed |
| 42182326 | De novo design of transmembrane accessory subunits for fold stabilization and expansion. | bioRxiv | 2026 | https://conductscience.org/library/papers/42182326 | PubMed |
| 42085239 | Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis. | Am J Respir Crit Care Med | 2026 | https://conductscience.org/library/papers/42085239 | PubMed |
| 41998105 | A cell-permeable nanobody to restore F508del cystic fibrosis transmembrane conductance regulator activity. | Nat Chem Biol | 2026 | https://conductscience.org/library/papers/41998105 | PubMed |
| 41920076 | Altered functional interactions between CFTR disease mutants ΔF508 and G551D and the protein kinase A catalytic subunit. | J Physiol | 2026 | https://conductscience.org/library/papers/41920076 | PubMed |
| 41915736 | Single-molecule dissection of CFTR folding defects and pharmacological rescue. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41915736 | PubMed |
| 41898631 | Distinct CFTR Mutation Spectrum and Atypical Clinical Presentations in Chinese Patients with Cystic Fibrosis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41898631 | PubMed |
| 41576103 | Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41576103 | PubMed |
| 41482647 | Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis. | Ther Adv Respir Dis | 2026 | https://conductscience.org/library/papers/41482647 | PubMed |
| 41379933 | General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants. | Elife | 2025 | https://conductscience.org/library/papers/41379933 | PubMed |
| 41258017 | In vivo conformational space and defects of misfolded CFTR variants by covalent protein painting. | Nat Commun | 2025 | https://conductscience.org/library/papers/41258017 | PubMed |
| 41235117 | Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41235117 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36264792
GET https://conductscience.org/api/papers/v1/36264792/references?page=2